Finance entity
Every one of those 2 sits in a single category, earnings. Of the tracked stories, 1 of 2 also mention Interventional MRI, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, earnings. Of the tracked stories, 1 of 2 also mention Interventional MRI, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 2 Finance stories that mention TULSA-PRO, all published on March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TULSA-PRO. Shared-story counts are live from our verified record — not editorial picks.
PROF Break-even
Target window for Profound Medical to reach cash-flow neutrality.
Kura NDA Submission
Anticipated filing for ziftomenib with the FDA.
Q4 Earnings Release
Both companies report pivotal year-end results.
CPT Code Activation
Category 1 CPT codes for TULSA-PRO go live in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Profound Medical and OptimizeRx reported robust fourth-quarter and full-year 2025 financial results, signaling a significant uptick in the adoption of MRI-guided interventions and digital life sciences engagement. The reports highlight a broader recovery in healthcare technology spending and a shift toward precision-based medical outcomes.
TULSA-PRO is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
